Targeted therapies in bladder cancer--an update

Area of Science:

• Oncology
• Molecular Biology
• Urology

Background:

• Bladder cancer management relies on immuno- and chemotherapy, surgery, and systemic treatments.
• Novel therapeutic strategies are needed to enhance patient outcomes.
• Targeted therapies offer a promising approach by focusing on specific molecular pathways.

Purpose of the Study:

• To review research on targeting growth factors and their receptors in bladder cancer.
• To summarize basic science, translational, and clinical research in this area.
• To explore the potential of novel agents for bladder cancer treatment.

Main Methods:

• Review of existing literature and ongoing research.
• Focus on epidermal growth factor receptor (EGFR) targeted therapy.
• Investigation of platelet-derived growth factor receptor-beta (PDGFR-beta), human EGF receptor 2 (HER2), fibroblast growth factor receptor 3 (FGFR3), and vascular endothelial growth factor (VEGF).

Main Results:

• EGFR-targeted therapy has shown disappointing clinical efficacy, necessitating the identification of predictive markers.
• Preclinical findings suggest PDGFR-beta as a potential target.
• FGFR3 mutations are implicated in bladder cancer, offering a therapeutic target.
• VEGF targeting is also under investigation.

Conclusions:

• Targeting specific molecular pathways, such as growth factor receptors, is a key strategy for advancing bladder cancer treatment.
• Identifying predictive biomarkers is crucial for the success of targeted therapies like EGFR inhibitors.
• Future directions may involve multi-kinase inhibitors or combination therapies to improve treatment efficacy.